Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic kidney disease (ADPKD) for $800 million upfront in a deal that could have a ...

TIOBE Index for February 2026: Top 10 Most Popular Programming Languages Your email has been sent February’s TIOBE Index shows a leaderboard that looks steady at first glance, but small shifts beneath ...

This week - the enterprise has a newfound obsession with "quality data" - but are we on the wrong track for AI? Pega and HubSpot turn in strong earnings, but Wall Street's AI fever (dreams?) persist.